Detalhe da pesquisa
1.
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Ann Oncol;
35(2): 221-228, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072158
2.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Oral Oncol;
147: 106587, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37925894
3.
'Rare cancers': not all together in clinical studies!
Ann Oncol;
33(5): 463-465, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131451
4.
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.
ESMO Open;
6(6): 100309, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34844180
5.
Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.
Endocrine;
73(3): 641-647, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33797698
6.
Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
Oral Oncol;
113: 105042, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583513
7.
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol;
32(4): 452-465, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358989
8.
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol;
31(11): 1462-1475, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239190
9.
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ann Oncol;
31(7): 942-950, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294530
10.
Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.
Oral Oncol;
97: 99-104, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31472438
11.
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
Eur J Cancer;
110: 62-70, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30771738
12.
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Ann Oncol;
29(12): 2313-2327, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307465
13.
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells.
Ann Oncol;
29(7): 1598-1600, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29897400
14.
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Eur J Cancer;
97: 7-15, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29734047
15.
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).
Ann Oncol;
29(4): 985-991, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29346507
16.
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells.
Ann Oncol;
29(7): 1599-1601, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32138836
17.
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Eur J Cancer;
86: 334-348, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29073584
18.
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
Ann Oncol;
28(11): 2813-2819, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045520
19.
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Ann Oncol;
28(11): 2820-2826, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950305
20.
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Ann Oncol;
28(10): 2526-2532, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961833